title: Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.
abstract: Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35+/-7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV+Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively).
authors.affiliation: Department of Pediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
authors.forename: Lucy Chai See
authors.initials: LC
authors.lastname: Lum
authors.forename: Charissa Fay
authors.initials: CF
authors.lastname: Borja-Tabora
authors.forename: Robert F
authors.initials: RF
authors.lastname: Breiman
authors.forename: Timo
authors.initials: T
authors.lastname: Vesikari
authors.forename: Benjamin P
authors.initials: BP
authors.lastname: Sablan
authors.forename: Oh Moh
authors.initials: OM
authors.lastname: Chay
authors.forename: Taweewong
authors.initials: T
authors.lastname: Tantracheewathorn
authors.forename: Heinz-Josef
authors.initials: HJ
authors.lastname: Schmitt
authors.forename: Yu-Lung
authors.initials: YL
authors.lastname: Lau
authors.forename: Piyaporn
authors.initials: P
authors.lastname: Bowonkiratikachorn
authors.forename: John S
authors.initials: JS
authors.lastname: Tam
authors.forename: Bee Wah
authors.initials: BW
authors.lastname: Lee
authors.forename: Kah Kee
authors.initials: KK
authors.lastname: Tan
authors.forename: Jerzy
authors.initials: J
authors.lastname: Pejcz
authors.forename: Sungho
authors.initials: S
authors.lastname: Cha
authors.forename: Maricruz
authors.initials: M
authors.lastname: Gutierrez-Brito
authors.forename: Petras
authors.initials: P
authors.lastname: Kaltenis
authors.forename: Andre
authors.initials: A
authors.lastname: Vertruyen
authors.forename: Hanna
authors.initials: H
authors.lastname: Czajka
authors.forename: Jurgis
authors.initials: J
authors.lastname: Bojarskas
authors.forename: W Abdullah
authors.initials: WA
authors.lastname: Brooks
authors.forename: Sheau-Mei
authors.initials: SM
authors.lastname: Cheng
authors.forename: Ruth
authors.initials: R
authors.lastname: Rappaport
authors.forename: Sherryl
authors.initials: S
authors.lastname: Baker
authors.forename: William C
authors.initials: WC
authors.lastname: Gruber
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Forrest
mesh_terms: D000281:Administration, Intranasal; D000914:Antibodies, Viral / Q000097:blood; D004344:Drug Incompatibility; D005260:Female; D006801:Humans; D007223:Infant; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control; D008297:Male; D008457:Measles / Q000517:prevention & control; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology*; D009107:Mumps / Q000517:prevention & control; D010919:Placebos / Q000008:administration & dosage; D012409:Rubella / Q000517:prevention & control; D014611:Vaccination / Q000379:methods*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines; D022542:Measles-Mumps-Rubella Vaccine; D010919:Placebos; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined